Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C
We systematically reviewed the evidence for long‐term effectiveness and cost‐effectiveness of antiviral treatment in patients with chronic hepatitis C. We performed a systematic literature search on the long‐term effectiveness and cost‐effectiveness of AVT in hepatitis C (1990–March 2007), and inclu...
Gespeichert in:
| Veröffentlicht in: | Journal of viral hepatitis 2010-01, Vol.17 (1), p.34-50 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 50 |
|---|---|
| container_issue | 1 |
| container_start_page | 34 |
| container_title | Journal of viral hepatitis |
| container_volume | 17 |
| creator | Sroczynski, G. Esteban, E. Conrads-Frank, A. Schwarzer, R. Mühlberger, N. Wright, D. Zeuzem, S. Siebert, U. |
| description | We systematically reviewed the evidence for long‐term effectiveness and cost‐effectiveness of antiviral treatment in patients with chronic hepatitis C. We performed a systematic literature search on the long‐term effectiveness and cost‐effectiveness of AVT in hepatitis C (1990–March 2007), and included health technology assessment (HTA) reports, systematic reviews, long‐term clinical trials, economic studies conducted alongside clinical trials and decision‐analytic modelling studies. All costs were converted to 2005€. Antiviral therapy with peginterferon plus ribavirin in treatment‐naïve patients with chronic hepatitis C was the most effective (3.6–4.7 life years gained [LYG]) treatment and was reasonably cost‐effective (cost‐saving to 84 700€/quality adjusted life years [QALY]) when compared to interferon plus ribavirin. Some results also suggest cost‐effectiveness (below 8400€/(QALY) of re‐treatment in nonresponders/relapsers. Results for patients with persistently normal alanine aminotransferase (ALT) levels or with special co‐morbidities (e.g. HIV) or risk profiles were rare. We conclude that antiviral therapy may prolong life, improve long‐term health‐related quality‐of‐life and be reasonably cost‐effective in treatment‐naïve patients with chronic hepatitis C as well as in former relapsers/nonresponders. Further research is needed in patients with specific co‐morbidities or risk profiles. |
| doi_str_mv | 10.1111/j.1365-2893.2009.01147.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_734230394</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734230394</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4547-54735e89fb07d913b3e142dd9213fcb827701a08526f983b6d7d2b7117e556933</originalsourceid><addsrcrecordid>eNp9kctOwzAQRS0EolD4BZQVrBL8iON4wQJVkAIVbAosLSeZgEseJXah_XsSWorYYMnyeO65ljUXIY_ggHTrfBYQFnGfxpIFFGMZYEJCESx30MFW2O1rTn3McThAh9bOMCaMcrKPBkRGPKISH6DppKlffAdt5UFRQObMB9Rgrafr3Msa6_y_7abolO5mWl16rgXtKqidZ2rvFebaGWesNzpCe4UuLRxvziF6vL6ajsb-5CG5GV1O_CzkofC7zTjEskixyCVhKQMS0jyXlLAiS2MqBCYax5xGhYxZGuUip6kgRADnkWRsiM7W787b5n0B1qnK2AzKUtfQLKwSLKQMMxl25Om_JCU0wnH3hyE62YCLtIJczVtT6XalfibWARdr4NOUsPrVseqTUTPVB6D6AFSfjPpORi3V7dO4rzq_v_Yb62C59ev2TUWCCa6e7xNFqZwk_C5WCfsC09aPKw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21260891</pqid></control><display><type>article</type><title>Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Sroczynski, G. ; Esteban, E. ; Conrads-Frank, A. ; Schwarzer, R. ; Mühlberger, N. ; Wright, D. ; Zeuzem, S. ; Siebert, U.</creator><creatorcontrib>Sroczynski, G. ; Esteban, E. ; Conrads-Frank, A. ; Schwarzer, R. ; Mühlberger, N. ; Wright, D. ; Zeuzem, S. ; Siebert, U.</creatorcontrib><description>We systematically reviewed the evidence for long‐term effectiveness and cost‐effectiveness of antiviral treatment in patients with chronic hepatitis C. We performed a systematic literature search on the long‐term effectiveness and cost‐effectiveness of AVT in hepatitis C (1990–March 2007), and included health technology assessment (HTA) reports, systematic reviews, long‐term clinical trials, economic studies conducted alongside clinical trials and decision‐analytic modelling studies. All costs were converted to 2005€. Antiviral therapy with peginterferon plus ribavirin in treatment‐naïve patients with chronic hepatitis C was the most effective (3.6–4.7 life years gained [LYG]) treatment and was reasonably cost‐effective (cost‐saving to 84 700€/quality adjusted life years [QALY]) when compared to interferon plus ribavirin. Some results also suggest cost‐effectiveness (below 8400€/(QALY) of re‐treatment in nonresponders/relapsers. Results for patients with persistently normal alanine aminotransferase (ALT) levels or with special co‐morbidities (e.g. HIV) or risk profiles were rare. We conclude that antiviral therapy may prolong life, improve long‐term health‐related quality‐of‐life and be reasonably cost‐effective in treatment‐naïve patients with chronic hepatitis C as well as in former relapsers/nonresponders. Further research is needed in patients with specific co‐morbidities or risk profiles.</description><identifier>ISSN: 1352-0504</identifier><identifier>EISSN: 1365-2893</identifier><identifier>DOI: 10.1111/j.1365-2893.2009.01147.x</identifier><identifier>PMID: 19656290</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Antiviral Agents - economics ; Antiviral Agents - therapeutic use ; antiviral treatment ; chronic hepatitis C ; Cost-Benefit Analysis ; cost-effectiveness ; effectiveness ; Hepatitis C - drug therapy ; Hepatitis C - economics ; Human immunodeficiency virus ; Humans ; Interferons - economics ; Interferons - therapeutic use ; Ribavirin - economics ; Ribavirin - therapeutic use ; Treatment Outcome</subject><ispartof>Journal of viral hepatitis, 2010-01, Vol.17 (1), p.34-50</ispartof><rights>2009 Blackwell Publishing Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4547-54735e89fb07d913b3e142dd9213fcb827701a08526f983b6d7d2b7117e556933</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2893.2009.01147.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2893.2009.01147.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19656290$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sroczynski, G.</creatorcontrib><creatorcontrib>Esteban, E.</creatorcontrib><creatorcontrib>Conrads-Frank, A.</creatorcontrib><creatorcontrib>Schwarzer, R.</creatorcontrib><creatorcontrib>Mühlberger, N.</creatorcontrib><creatorcontrib>Wright, D.</creatorcontrib><creatorcontrib>Zeuzem, S.</creatorcontrib><creatorcontrib>Siebert, U.</creatorcontrib><title>Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C</title><title>Journal of viral hepatitis</title><addtitle>J Viral Hepat</addtitle><description>We systematically reviewed the evidence for long‐term effectiveness and cost‐effectiveness of antiviral treatment in patients with chronic hepatitis C. We performed a systematic literature search on the long‐term effectiveness and cost‐effectiveness of AVT in hepatitis C (1990–March 2007), and included health technology assessment (HTA) reports, systematic reviews, long‐term clinical trials, economic studies conducted alongside clinical trials and decision‐analytic modelling studies. All costs were converted to 2005€. Antiviral therapy with peginterferon plus ribavirin in treatment‐naïve patients with chronic hepatitis C was the most effective (3.6–4.7 life years gained [LYG]) treatment and was reasonably cost‐effective (cost‐saving to 84 700€/quality adjusted life years [QALY]) when compared to interferon plus ribavirin. Some results also suggest cost‐effectiveness (below 8400€/(QALY) of re‐treatment in nonresponders/relapsers. Results for patients with persistently normal alanine aminotransferase (ALT) levels or with special co‐morbidities (e.g. HIV) or risk profiles were rare. We conclude that antiviral therapy may prolong life, improve long‐term health‐related quality‐of‐life and be reasonably cost‐effective in treatment‐naïve patients with chronic hepatitis C as well as in former relapsers/nonresponders. Further research is needed in patients with specific co‐morbidities or risk profiles.</description><subject>Antiviral Agents - economics</subject><subject>Antiviral Agents - therapeutic use</subject><subject>antiviral treatment</subject><subject>chronic hepatitis C</subject><subject>Cost-Benefit Analysis</subject><subject>cost-effectiveness</subject><subject>effectiveness</subject><subject>Hepatitis C - drug therapy</subject><subject>Hepatitis C - economics</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Interferons - economics</subject><subject>Interferons - therapeutic use</subject><subject>Ribavirin - economics</subject><subject>Ribavirin - therapeutic use</subject><subject>Treatment Outcome</subject><issn>1352-0504</issn><issn>1365-2893</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kctOwzAQRS0EolD4BZQVrBL8iON4wQJVkAIVbAosLSeZgEseJXah_XsSWorYYMnyeO65ljUXIY_ggHTrfBYQFnGfxpIFFGMZYEJCESx30MFW2O1rTn3McThAh9bOMCaMcrKPBkRGPKISH6DppKlffAdt5UFRQObMB9Rgrafr3Msa6_y_7abolO5mWl16rgXtKqidZ2rvFebaGWesNzpCe4UuLRxvziF6vL6ajsb-5CG5GV1O_CzkofC7zTjEskixyCVhKQMS0jyXlLAiS2MqBCYax5xGhYxZGuUip6kgRADnkWRsiM7W787b5n0B1qnK2AzKUtfQLKwSLKQMMxl25Om_JCU0wnH3hyE62YCLtIJczVtT6XalfibWARdr4NOUsPrVseqTUTPVB6D6AFSfjPpORi3V7dO4rzq_v_Yb62C59ev2TUWCCa6e7xNFqZwk_C5WCfsC09aPKw</recordid><startdate>201001</startdate><enddate>201001</enddate><creator>Sroczynski, G.</creator><creator>Esteban, E.</creator><creator>Conrads-Frank, A.</creator><creator>Schwarzer, R.</creator><creator>Mühlberger, N.</creator><creator>Wright, D.</creator><creator>Zeuzem, S.</creator><creator>Siebert, U.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>201001</creationdate><title>Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C</title><author>Sroczynski, G. ; Esteban, E. ; Conrads-Frank, A. ; Schwarzer, R. ; Mühlberger, N. ; Wright, D. ; Zeuzem, S. ; Siebert, U.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4547-54735e89fb07d913b3e142dd9213fcb827701a08526f983b6d7d2b7117e556933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Antiviral Agents - economics</topic><topic>Antiviral Agents - therapeutic use</topic><topic>antiviral treatment</topic><topic>chronic hepatitis C</topic><topic>Cost-Benefit Analysis</topic><topic>cost-effectiveness</topic><topic>effectiveness</topic><topic>Hepatitis C - drug therapy</topic><topic>Hepatitis C - economics</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Interferons - economics</topic><topic>Interferons - therapeutic use</topic><topic>Ribavirin - economics</topic><topic>Ribavirin - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sroczynski, G.</creatorcontrib><creatorcontrib>Esteban, E.</creatorcontrib><creatorcontrib>Conrads-Frank, A.</creatorcontrib><creatorcontrib>Schwarzer, R.</creatorcontrib><creatorcontrib>Mühlberger, N.</creatorcontrib><creatorcontrib>Wright, D.</creatorcontrib><creatorcontrib>Zeuzem, S.</creatorcontrib><creatorcontrib>Siebert, U.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of viral hepatitis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sroczynski, G.</au><au>Esteban, E.</au><au>Conrads-Frank, A.</au><au>Schwarzer, R.</au><au>Mühlberger, N.</au><au>Wright, D.</au><au>Zeuzem, S.</au><au>Siebert, U.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C</atitle><jtitle>Journal of viral hepatitis</jtitle><addtitle>J Viral Hepat</addtitle><date>2010-01</date><risdate>2010</risdate><volume>17</volume><issue>1</issue><spage>34</spage><epage>50</epage><pages>34-50</pages><issn>1352-0504</issn><eissn>1365-2893</eissn><abstract>We systematically reviewed the evidence for long‐term effectiveness and cost‐effectiveness of antiviral treatment in patients with chronic hepatitis C. We performed a systematic literature search on the long‐term effectiveness and cost‐effectiveness of AVT in hepatitis C (1990–March 2007), and included health technology assessment (HTA) reports, systematic reviews, long‐term clinical trials, economic studies conducted alongside clinical trials and decision‐analytic modelling studies. All costs were converted to 2005€. Antiviral therapy with peginterferon plus ribavirin in treatment‐naïve patients with chronic hepatitis C was the most effective (3.6–4.7 life years gained [LYG]) treatment and was reasonably cost‐effective (cost‐saving to 84 700€/quality adjusted life years [QALY]) when compared to interferon plus ribavirin. Some results also suggest cost‐effectiveness (below 8400€/(QALY) of re‐treatment in nonresponders/relapsers. Results for patients with persistently normal alanine aminotransferase (ALT) levels or with special co‐morbidities (e.g. HIV) or risk profiles were rare. We conclude that antiviral therapy may prolong life, improve long‐term health‐related quality‐of‐life and be reasonably cost‐effective in treatment‐naïve patients with chronic hepatitis C as well as in former relapsers/nonresponders. Further research is needed in patients with specific co‐morbidities or risk profiles.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>19656290</pmid><doi>10.1111/j.1365-2893.2009.01147.x</doi><tpages>17</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1352-0504 |
| ispartof | Journal of viral hepatitis, 2010-01, Vol.17 (1), p.34-50 |
| issn | 1352-0504 1365-2893 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_734230394 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Antiviral Agents - economics Antiviral Agents - therapeutic use antiviral treatment chronic hepatitis C Cost-Benefit Analysis cost-effectiveness effectiveness Hepatitis C - drug therapy Hepatitis C - economics Human immunodeficiency virus Humans Interferons - economics Interferons - therapeutic use Ribavirin - economics Ribavirin - therapeutic use Treatment Outcome |
| title | Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T12%3A38%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20effectiveness%20and%20cost-effectiveness%20of%20antiviral%20treatment%20in%20hepatitis%20C&rft.jtitle=Journal%20of%20viral%20hepatitis&rft.au=Sroczynski,%20G.&rft.date=2010-01&rft.volume=17&rft.issue=1&rft.spage=34&rft.epage=50&rft.pages=34-50&rft.issn=1352-0504&rft.eissn=1365-2893&rft_id=info:doi/10.1111/j.1365-2893.2009.01147.x&rft_dat=%3Cproquest_pubme%3E734230394%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=21260891&rft_id=info:pmid/19656290&rfr_iscdi=true |